Results from three clinical trials involving the inves­ti­ga­tional drug filanesib were presented at the American Society of Hematology (ASH) annual meeting earlier this month.

The trials evaluated the efficacy of filanesib (ARRY-520) alone and in com­bi­na­tion with other agents as potential treat­ments for re­lapsed and refractory multiple myeloma patients.

Overall, the trial results presented at ASH con­firm existing impressions of filanesib as a promising potential myeloma ther­apy.

Results of a Phase 2 trial of filanesib with or without low-dose dex­a­meth­a­sone (Decadron) show that 16 per­cent of patients who …

This Monday was the third day of the 2013 American Society of Hema­tol­o­gy (ASH) annual meeting, which was held in New Orleans.

More than any other day of the conference, Monday was packed with im­por­tant myeloma pre­sen­ta­tions, from 7:00 in the morning until almost 8:00 in the eve­ning.

This ASH update will summarize the oral pre­sen­ta­tion sessions about treat­ment-related myeloma studies that were held Monday morning. An ASH update that was pub­lished on Wednesday focused on the sessions that were held Monday afternoon and evening.

Monday morning started with three simultaneous …

This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.

Myeloma-related presentations were made during several sessions yesterday.

Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.

The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as pre­clin­i­cal and clin­i­cal studies testing new and existing treat­ments for myeloma.

During the session, research results were made avail­able for review by meeting attendees in the form …

The Beacon con­tinues today with its ‘ASH preview’ series about mye­lo­ma re­search that will be pre­sented at the American Society of Hema­tol­o­gy (ASH) meet­ing in early December.

Abstracts for the ASH presentations are now avail­able, although many con­tain pre­lim­i­nary in­­for­ma­tion that will be updated at the meet­ing.

The Beacon’s ASH preview articles are in­tended to highlight the meet­ing's most in­ter­est­ing myeloma-related studies.

The first and second previews, published earlier this week and last week, provide an overview of ASH abstracts about the newest poten­tial mye­lo­ma ther­a­pies just starting out in clin­i­cal trials.  Further previews will …

Boulder, CO (Press Release) - Array BioPharma Inc. (NASDAQ: ARRY) today announced that five abstracts were accepted for presentation, in­­clud­ing two oral presentations, at the 2013 Annual Meeting of the Ameri­can Society of Hematology (ASH) on its two wholly-owned hematology drug can­di­dates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor.

Ron Squarer, Chief Executive Officer of Array, noted, "We look forward to the oppor­tu­ni­ty to present updates on ARRY-520 and ARRY-614 at the ASH meeting.  We believe that results from multiple clin­i­cal and pre­clin­i­cal studies of ARRY-520 will both dem­onstrate its …

Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year.  The first education and poster sessions of the meet­ing will take place tomorrow, Friday, June 14.  Additional sessions of vari­ous kinds are scheduled for both days of the weekend, until the meet­ing ends early Sunday afternoon (European time).

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related dis­eases, in­clud­ing multiple myeloma.

The EHA meeting is …

Looking back at all that has hap­pened in the world of mul­ti­ple myeloma since Jan­u­ary of 2012, it is hard not to be impressed by the many im­por­tant devel­op­ments that took place.

There is the obvious fact that, during that time, not one, but two new drugs to treat myeloma were approved by the U.S. Food and Drug Adminis­tra­tion (FDA).  Prior to 2012, the FDA had not approved a novel anti-myeloma ther­apy in over six years.

Yet 2012 was meaningful to the myeloma com­munity for reasons beyond the ac­­tiv­ity at the FDA’s …